Zoulim and colleagues demonstrate in cell culture and in preclinical mouse models that hepatitis B virus (HBV) replication and antigen production can be durably abrogated by the use of base editing technology to introduce permanent mutations in the HBV genome, opening new perspectives toward a cure for chronic HBV infection.
All Keywords
【저자키워드】 Therapeutics, Lipid nanoparticles, HBV, gene editing, HBsAg, cccDNA, base editing, MT: RNA/DNA Editing,
【저자키워드】 Therapeutics, Lipid nanoparticles, HBV, gene editing, HBsAg, cccDNA, base editing, MT: RNA/DNA Editing,